Earnings Sentiment

Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.

Please consider a small donation if you think this website provides you with relevant information  

    

Sentiment Distribution

   

Earnings Call Transcript Word Cloud

     

Bullish Statements during Earnings call

Statement
Ray, as you know, I've always been an extremely supportive and appreciative of management shareholder for many, many, many years
American Shared had another solid quarter, with year-over-year revenue increasing by 6.3% to $5.1 million for the third quarter
AMS consistently generates positive cash flow even throughout the pandemic
There's been costs associated with just regulatory filings that are necessary to obtain the business and other consultants and advisers that we feel has been very beneficial to enhance our ability to close the opportunities
In closing, we've built good momentum both internationally and in the U.S., and AMS has a full pipeline of opportunities and is supported by a strong financial position
As far as our stock price, I think as I've often mentioned, I really believe our stock is undervalued
We're excited about that future
So all I can say is keep in touch, our stock is undervalued
We're especially excited by three unique opportunities, which we first mentioned on our last call
I'm proud to say that AMS will have the most advanced radiation cancer treatment system in their region when the installations are complete
Our in-house customer advocate has been a great addition
And our business order intake, our pipeline has been growing and our order intake is slowly increasing our rate of orders that we're taking in is increasing
He has also continued to help improve the activity levels on our Gamma Knife sites
We continue to maintain a tight rein on direct costs and the gross margin grew 7.4% to $2.1 million
The booth was fully staffed with our team, and it was a great opportunity for us to meet with customers, partners and OEMs
Internationally, the installation of new equipment with expanded treatment offerings at two of our locations has progressed well
We attribute this growth to our sales team, which has hit its stride and our expanded financial solutions and closer integration with our strategic OEMs on targeted prospects
We're a profitable company
In the third quarter, Gamma Knife procedures increased approximately 8% period-over-period after improving the utilization in the second quarter as well
During the third quarter, the sales pipeline continued to grow
We're growing, and we're going to grow more incrementally
I really believe American shares never been in a stronger position with the pipeline opportunities we have, our financial position, capital we have ready to be deployed
In closing, I hope I've conveyed some of the excitement that we all feel here at AMS
Domestic revenue was $4.1 million, an increase of 1.1% and international revenue was $1 million compared to $727,000 a year ago, an increase of 35.9%
Third quarter revenue increased 6.3% to $5.1 million compared to $4.8 million in the year ago period
I think our performance has been steady
Total Gamma Knife revenue increased 9.9% to $2.7 million
Be well, and have a great evening
We also attended three conferences in Ecuador this year, where we've developed great referral sources
In the third quarter, we invested approximately $320,000, advancing these unique opportunities
       

Bearish Statements during earnings call

Statement
And I think our recent stock price decline, I think the market misunderstood some of our recent, in particular, second quarter, let's say, we reported a loss, and we had a couple of blips in our second quarter
Third quarter revenue for the proton therapy system in Florida was $2.2 million, a decrease of 5.9% primarily due to a decrease in fractions, offset by continued increases in average reimbursement
The stock is down 15% since just the last conference call
To me, that would signal that your growth opportunities were not as robust as maybe
Total proton therapy fractions in the third quarter were 1,188, a decrease of 12.8% or 175 fractions
The decrease was primarily due to higher interest expense and higher selling and administrative expense in support of the company's new business opportunities
This quarter, we reported a profit
Actual results may vary materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the company's filings with the SEC
There's been legal costs
The decrease was primarily due to lower earnings, return to provision adjustments arising from foreign tax returns and permanent domestic tax differences
   

Please consider a small donation if you think this website provides you with relevant information